|Bid||30.15 x 100|
|Ask||36.85 x 100|
|Day's range||37.50 - 39.13|
|52-week range||24.66 - 49.16|
|PE ratio (TTM)||N/A|
|Earnings date||4 May 2017 - 8 May 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||51.00|
Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue. For 2017 and 2018, Radius Health is expected to post revenue of $23 million and $97.7 million, respectively. Array Biopharma (ARRY) is expected to report revenue of $108 million in 2018.
The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis. Another candidate is the investigational drug elacestrant (or RAD1901), which is a selective estrogen receptor degrader for the treatment of hormone receptor-positive breast cancer and the treatment of vasometer symptoms in postmenopausal women. The pipeline also includes the investigational drug RAD140, a nonsteroidal selective androgen receptor modulator, for its potential use in treating hormone receptor-positive breast cancer.
Radius Health (RDUS) is a biopharmaceutical company that has recently turned into a commercial stage healthcare company. Of the seven analysts covering Radius Health in January 2018, three have given the stock “buy” or higher ratings, while four have given it “hold” ratings. The mean rating for the stock is 2.43, and it has a target price of $47.5.
WALTHAM, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California.
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) announced today that Elhan Webb has joined the Company as Head of Investor Relations and External Communications. “We are very fortunate to have someone of Elhan’s caliber to drive our Investor Relations strategy during a pivotal time in the evolution of Radius,” said Jesper Høiland, President and Chief Executive Officer of Radius Health. Ms. Webb is a CFA® charterholder and joins Radius from Genfit Corporation where she was Vice President and Head of Investor Relations.
Radius Health (RDUS) will get a third Day-180 List of Outstanding Issues from the CHMP for its marketing authorisation application of abaloparatide-SC leading to a further delay in tentative approval.
On a day the indexes closed at record highs, shares of ForeScout soared on strong revenue growth, and Radius Health jumped following encouraging drug trial results.
Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.
Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.
Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.